To determine the feasibility and cost of home antibiotic therapy for a select group of neonates.
Treatment of presumed or culture-proven neonatal sepsis remains a common medical problem, with the most common pathogen in the United States being group B streptococcus (GBS). 1, 2 In infants with suspected or blood culture-proven sepsis, clinical presentation varies considerably. Some neonates require intensive care management for the treatment of sepsis, whereas others do not. Certain maternal conditions such as prolonged rupture of membranes or maternal fever may necessitate maternal antimicrobial therapy that possibly invalidates the infant's blood culture. Despite negative blood culture results, some infants have a clinical course consistent with sepsis labeled as "presumed sepsis."
The large proportion of neonates who initially present with signs or indicators consistent with sepsis show improvement and appear well within 48 to 72 hours after the onset of antimicrobial therapy. These infants historically have been prescribed 7 to 10 days of parenteral therapy administered in the inpatient hospital setting. During the past decade, there has been a trend to discharge such infants on home antibiotic therapy, thus completing the therapeutic course as outpatients.
Concern has been raised that the criteria applied to this subgroup of neonates who receive home antibiotic therapy are variable, and that outcome data are rarely available regarding the ease and success of this mode of therapy. We sought to prospectively study a group of neonates who met the criteria for previously established outpatient antibiotic therapy at a university-based hospital to determine the continued feasibility and cost of home antibiotic therapy.
METHODS
First, approval for this study was obtained from the Medical University of South Carolina's Institutional Review Board for Human Research. Subsequently, neonates who met criteria for home antibiotic therapy at discharge were prospectively followed during the period from November 1995 to October 1997. The criteria for home antibiotic therapy eligibility included one of the following diagnoses: (1) Positive blood culture with susceptible organisms; (2) clinical sepsis (negative blood culture) with initial presentation of hypotension, tachypnea, or poor perfusion with an abnormal immature to total neutrophil count; (3) pneumonia defined by the attending radiologist's reading of an infiltrate on chest x-ray and clinical signs such as tachypnea or need for supplemental oxygen; and (4) culture-proven meningitis with negative follow-up culture or suspected meningitis (culture-negative). Patients meeting criteria 1 through 3 were eligible for continuation of antimicrobial therapy at home after at least 4 days of in-hospital antibiotic therapy and if their clinical status had normalized for at least 48 hours before discharge. Those patients meeting criterion 4 (meningitis) were eligible for continuation of therapy at home after a minimum of 10 days of in-hospital antibiotic therapy and normalized clinical status.
Before discharge, each patient eligible for home therapy had to meet specified discharge requirements, including prior approval by the primary insurance carrier of the infant (Table 1) . With regard to bilirubin levels, the stipulation was made that the indirect bilirubin would be Յ 8 according to a neonatology policy that had been in place for several years before initiation of this study. The level of 8 had been chosen a priori as a level that was unequivocally safe even if the bilirubin rose further secondary to its potential displacement from albumin by continued dosing of ceftriaxone. Thus, this policy insured that any potential displacement of bilirubin by ceftriaxone would not be associated with higher levels of bilirubin that could result in morbidity to the neonate.
When the discharge requirements were met, a discharge planning pathway was initiated ( Table 2 ). In the pathway, parental and community physician agreement and insurance company approval for home antibiotic therapy were first obtained; discharge on home therapy was contingent on their unanimous approval. Parents signed the discharge instruction sheet detailing the outpatient plans before discharge. Subsequently, parents received education regarding proper care of the intravascular (i.v.) site. Specifically, parents were taught to evaluate the patency of the i.v., to flush the i.v. with heparin/saline every 8 hours, and to identify signs of inflammation or induration. Before discharge, parents also were taught to recognize signs and symptoms of septic shock, anaphylaxis, and change in respiratory status.
The infant was discharged to home with the stipulation that the physician be briefed regarding the patient's history and a discharge summary facsimile received. In addition, the physician had to agree to be readily available for the patient should the need arise. Patients were to be examined daily by the visiting nurse or physician to check for any change in clinical course. For a home health agency to be eligible for the care of a neonate, a pediatric-trained nurse with a minimum of 2 years postgraduate experience had to be identified. When ceftriaxone was prescribed, the first dose was given in the inpatient setting to watch for any allergic reaction. When antibiotic therapy was changed to ceftriaxone after discharge, the nurse was instructed to observe the infant for 1 hour after administration. Finally, when gentamicin was prescribed, a peak and trough were obtained before discharge, with follow-up levels obtained if necessary to ensure that blood serum levels of the drug were in the therapeutic range.
Data were collected prospectively on each patient who was discharged on home antibiotic therapy. The data included sample characteristics such as birth weight, gestational age (as defined by best obstetrical criteria), and indication for antibiotic therapy. Outcome variables included the following: (1) type of antibiotic therapy prescribed; (2) whether or not the type of antibiotic prescribed changed during the course of outpatient therapy; (3) the number, frequency, and route of doses of the drug(s) given as an outpatient; (4) duration of therapy in days; (5) route of antibiotic therapy (defined as intramuscular or i.v.) at the time of discharge from the hospital; (6) whether or not those infants receiving i.v. administration were later switched to intramuscular administration; (7) whether the patient required hospital read- mission during the course of therapy or within 30 days after discharge from the hospital; and (8) cost of hospitalization.
The cost of hospitalization was obtained from the University Hospital Cost Accounting Computing System (TrendStar). Hospital charges were determined from the amount billed for the entire hospitalization; bed, nursing, laboratory, and pharmacy charges were inclusive. Home health charges were obtained from each designated home health agency.
RESULTS
During the study period from November 1995 through October 1997, there were 4365 neonates admitted to the university hospital. Of this total, 240 were diagnosed with culture-proven sepsis, 496 with presumed sepsis, 126 with pneumonia, and 23 with meningitis. Of those neonates prescribed at least a 7-to 10-day course of antibiotic therapy (n ϭ 885 [20%]), 95 (11%) met home antibiotic treatment criteria. Of the 790 infants who did not meet home antibiotic treatment criteria, 357 were preterm, 3 were discharged to home on continued antiviral medications, and the remaining 430 still required intermediate or intensive care management at 5 days.
The mean Ϯ SD birth weight of the cohort was 3160 Ϯ 526 gm (range 2000 to 4647, median weight 3202 gm). The gestational age of the cohort as defined by best obstetrical dating was 38.4 Ϯ 2.1 weeks (range 34 to 42, median gestation age 39 weeks). The average age at discharge was 5.2 (range 4 to 12) days.
The indications for antibiotic therapy in this cohort are summarized in Table 3 . The most common reason was a clinical history consistent with sepsis (n ϭ 56 [59%]). A total of 11 of those neonates (12%) were born to mothers with risk factors for infection, who had received antibiotic therapy before delivery. The second most common indicator for antibiotic therapy was a diagnosis of pneumonia (n ϭ 24 [25%]), of which one case was blood culture-proven GBS. Treatment for presumed congenital syphilis was the third most common reason for home antibiotic therapy (n ϭ 9 [10%] ). Blood cultures were positive for GBS in three patients; as described above, one infant was also diagnosed with pneumonia. Three infants had GBSpositive cerebrospinal fluid.
The combination of ampicillin and gentamicin was prescribed for 53 infants (56%). The second most commonly prescribed medication was ceftriaxone (n ϭ 20 [21%]). At the time of discharge, all of the intravenous catheters in place were peripheral; no infant in this cohort was discharged with a percutaneous, intravenous, central catheter. After discharge, an additional four infants were switched from i.v. ampicillin/gentamicin therapy to intramuscular ceftriaxone due to loss of intravenous access (e.g., through loss of i.v. patency or through dislodgment). The remainder of the infants were discharged on ampicillin alone (n ϭ 10), penicillin (n ϭ 9), gentamicin alone (n ϭ 1), and nafcillin (n ϭ 2).
The average number of days the infants received home therapy was 4.7 Ϯ 3.9 days, and the median number of days was 4. Antibiotic dosing varied by antibiotic prescribed: every 8 hours for ampicillin, (12) When ceftriaxone was prescribed, the first dose was given in-house to watch for any allergic reaction. (13) If antibiotic treatment was changed to ceftriaxone after discharge, the nurse was to observe the infant for 1 hour postadministration. (14) When prescribed, gentamicin peak and trough obtained before discharge, with follow-up levels if necessary to ensure blood serum levels in therapeutic range. every 12 to 24 hours for gentamicin, and every 24 hours for ceftriaxone. Those infants discharged to home on ceftriaxone therapy previously had received ampicillin and gentamicin. As stated earlier, four infants were changed from intravenous ampicillin and gentamicin to ceftriaxone intramuscularly. Because of a bilirubin level of Ͼ8, four additional infants were changed from ceftriaxone back to ampicillin and gentamicin to complete coverage. Complications in this cohort consisted of readmission of two infants to the hospital due to various problems. With the first, the physician felt uncomfortable with home antibiotic therapy despite having agreed with the plan at discharge; with the second, the mother felt uncomfortable with the home health company delivering care to her infant. In another case, therapy was discontinued a day earlier due to loss of intravenous access and a decision made by the pediatrician to treat for 6 instead of 7 days. The infant, who otherwise appeared well, was being treated for presumed sepsis secondary to maternal infection and pretreatment. For the remaining 92 patients, home antibiotic therapy was completed as specified before discharge. No patients required treatment in an emergency department for replacement of a dislodged intravenous catheter or complications associated with the outpatient therapy. No patients required rehospitalization due to worsening clinical course or anaphylactic reaction to medication prescribed. No patient had a medication changed due to an allergic reaction suggested by a rash.
A total of 70 patients in the cohort had bilirubin levels drawn before discharge. The highest bilirubin mean for the group was 10.4 Ϯ 0.5 mg/dl (range 1 to 18.6). Before discharge, the mean bilirubin level had decreased to 8.1 Ϯ 0.4 mg/dl (range 0.8 to 14.9). Of the infants who were potentially to be discharged to home on ceftriaxone, the range of bilirubin levels was 0.8 to 10.7. Four of those infants whose bilirubin was Ͼ8 continued to receive ampicillin and gentamicin therapy rather than ceftriaxone. No infants were rehospitalized for hyperbilirubinemia.
Readmission after completion of the prescribed medical therapy was monitored for 6 months. There were two infants in the cohort who later required readmission to the hospital. The first infant had a diagnosis of viral enteritis at 6 weeks. The second infant was readmitted at 2 weeks of age for unspecified abdominal pain and again at 5 weeks for an unspecified acute viral infection. There were no documented treatment failures in this cohort.
A cost analysis of infants who received home antibiotic therapy versus projected continued in-hospital care revealed significant total cost differences between the modes of therapy. The cost of medication in the inpatient and outpatient settings was similar. The average hospital cost per patient for the entire group was $6221. The cost of hospitalization to the family was unknown and represented variations with each family, but potentially included hotel bills, costs of meals, travel, babysitters, lost time from work, etc. Home health charges included the cost of the nurse's visit and the medication, and varied by agency and by the number of daily doses of drug required. The average daily drug cost for both home therapy and projected inpatient treatment was $300 per day ($1500 for 5 days) for ampicillin and gentamicin therapy or $100 per day ($500 for 5 days) for ceftriaxone. Because home health care was an outpatient charge, this represented a cost to the family that varied by insurance type. Typically, families paid 20% of services up to their deductible for privately funded patients; there were no charges to the families of Medicaid patients. Many families, however, had already met their deductible after 5 days of in-hospital care for a family member. Excluding physician charges, the projected difference in cost between the two types of therapy was substantial. Compared with a 10-day inpatient stay, 5 days of inhospital care and 5 days of outpatient therapy provided a projected savings of $1200 (for every 8-hour drug administration) or $2250 (with once-daily antibiotic dosing).
DISCUSSION
In this study, a cohort of neonates diagnosed with an infectious process, who met criteria for home antibiotic therapy, was without complication or treatment failure; in addition, fewer projected costs were observed compared with continued inpatient therapy. Ampicillin and gentamicin combined or ceftriaxone were the most frequently prescribed therapies in this cohort.
Although other antibiotics such as cefotaxime were not precluded from use in this study, ceftriaxone was prescribed preferentially in this cohort given its once-daily dosing and previous experience with the drug at our institution. Thus, the use of ceftriaxone as the antimicrobial agent of choice was based on favorable pharmacokinetics of the drug and prior experience. Once-daily dosing of ceftriaxone achieves plasma levels that exceed the minimum inhibitory concentrations of a wide range of pathogenic organisms, including GBS. Rondanelli et al.
3 studied 14 newborns treated with ceftriaxone at gestational ages ranging from 31 to 42 weeks. The mean plasma concentrations 30 minutes after infusion were 181 Ϯ 20 g/ml, falling to 30 Ϯ 10 g/ml 24 hours after infusion. The mean half-life of the drug was 20 hours, the total clearance of the drug was 0.38 ml/kg per minute, and the volume of distribution was 0.32 l/kg. There was no correlation between clearance and postnatal age. In this small cohort, there were no observed side effects. Similar results were found in this cohort of neonates and by several other groups 4 -9 in their study of neonates. One major concern with the use of ceftriaxone in neonates is its potential to competitively displace bilirubin from albumin-binding sites. The bilirubin that is displaced is in the unconjugated form. At higher concentrations, this form of bilirubin has been associated with kernicterus. 5,10 -13 For this reason, the criteria that were followed when prescribing ceftriaxone for patients in this cohort included documentation of a bilirubin level of Յ8 mg/dl and no evidence of a hemolytic disease or process such as ABO incompatibility. There were four patients in the cohort who developed bilirubin levels of Ͼ8 that necessitated switching from a planned course of ceftriaxone to ampicillin and gentamicin therapy. None of those patients required an exchange transfusion. The bilirubin level of Յ8 was chosen a priori in prescribing ceftriaxone for outpatient therapy. This lower bilirubin level insured a safety margin that allowed for possible increases in bilirubin after discharge. As such, it is important that close follow-up be maintained to insure prompt patient evaluation should jaundice develop. With these restrictions in mind, ceftriaxone was used safely in this cohort in the outpatient setting. Compared with traditional ampicillin and gentamicin therapy in the outpatient setting, it also represents cost savings to families and insurance companies.
Other investigators have shown that outpatient parenteral antibiotic management of a select group of low-risk infants is an alternative to continued hospitalization in the clinically improved neonate. 14, 15 In addition, previous studies have cited certain benefits of outpatient or home antibiotic therapy, which include the following: (1) perceived psychological benefit for both infant and parents; (2) a decreased incidence of nosocomial infections (e.g., rotavirus, respiratory syncytial virus); and (3) a decrease in hospital costs and physician time (office visit versus hospital visit). 14, 15 Eligibility criteria vary by institution depending on the outpatient therapies available and the patient population served. Each institution should design a clinical care pathway that addresses its community's resources, including the ability to provide close patient follow-up after discharge.
The discharge planning that encompasses the family, the physician, and the home health company before discharge will have the greatest effect on successful completion of the infant's course of treatment in the outpatient setting. If the visiting nurse company is unfamiliar with maintaining or replacing intravenous catheters in neonates or unsure of the neonate's health status, one might expect more office visits, emergency department visits, and readmission to the hospital. Such increased care requirements would place undue burden on the patient, the family, and the health care system. It is imperative, then, that any outpatient/home health system for neonates be thoughtfully developed before implementation. The guidelines that were presented in this study may be used as a template.
In summary, a cohort of neonates diagnosed with an infectious process or presumed sepsis who met criteria for home antibiotic therapy was discharged to home without complication and with fewer projected costs than with continued inpatient therapy. A total of 93 of the 95 infants completed therapy as outpatients; there were no serious complications or treatment failures reported in any of the patients. Mild hyperbilirubinemia was documented in four infants who were begun on ceftriaxone before discharge; consequently, these infants were changed back to the initial medication prescribed. After discharge, four additional patients were switched from ampicillin and gentamicin to ceftriaxone due to loss of an intravenous catheter. Despite these medication changes, no patient in the cohort required rehospitalization due to treatment failure. With patients who have rapid recovery from infection and who meet early discharge criteria, home antibiotic therapy remains a viable, less costly alternative to continued in-hospital care.
